Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2024 Aug 31;16(8):e68349.
doi: 10.7759/cureus.68349. eCollection 2024 Aug.

Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants: A Review

Dhanvi Patel  1 , Jyotsna Chawla  2 , Cyril Blavo  3
Affiliations
Review

Use of the Abrysvo Vaccine in Pregnancy to Prevent Respiratory Syncytial Virus in Infants: A Review

Dhanvi Patel et al. Cureus. .

Abstract

The FDA's approval of Pfizer's new respiratory syncytial virus (RSV) prefusion (preF) vaccine, Abrysvo, marks a critical milestone in infant health and well-being by preventing lower respiratory tract infections in the most vulnerable. The vaccine has been approved for administration to pregnant women at 32 to 36 weeks of gestation and elderly people over 60. This review explores the Abrysvo vaccine, detailing its mechanism, efficacy, safety, and adverse events. It aims to inform healthcare providers about this vital method for safeguarding infant respiratory health through maternal immunization.

Keywords: abrysvo; adverse effects; fda approved; infant health; maternal vaccination; pregnancy; respiratory syncytial virus; rsv vaccine.

PubMed Disclaimer

Conflict of interest statement

Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Figures

Figure 1
Figure 1. Abrysvo maternal antibody transfer.
The process of passive immunization in infants at birth occurs through maternal vaccination, leading to antibody development in the mother subsequent to receiving the first FDA-approved RSV vaccine [16,17]. The illustration was created with BioRender.com. preF = pre-Fusion protein.
Figure 2
Figure 2. Preterm birth outcomes in Abrysvo vaccine phase 2b and 3 trial.
Results of the phase 2b and 3 trials identifying increase in preterm births in Abrysvo administration during 24 to 36 weeks of gestation compared to the approved 32 to 36 weeks of gestation [14]. The figure was adapted from clinical trial data assessment results [14].
See this image and copyright information in PMC

Similar articles

See all similar articles

References

    1. Respiratory syncytial virus: infection, detection, and new options for prevention and treatment. Griffiths C, Drews SJ, Marchant DJ. Clin Microbiol Rev. 2017;30:277–319. - PMC - PubMed
    1. RSV-NET Interactive Dashboard. Centers for Disease Control and Prevention. [ Jun; 2024 ]. 2024. https://www.cdc.gov/rsv/research/rsv-net/dashboard.html https://www.cdc.gov/rsv/research/rsv-net/dashboard.html
    1. Respiratory syncytial virus infection: old challenges and new approaches. Ramilo O, Rodriguez-Fernandez R, Mejias A. J Infect Dis. 2023;228:4–7. - PMC - PubMed
    1. Evolution of the immune system in humans from infancy to old age. Simon AK, Hollander GA, McMichael A. Proc Biol Sci. 2015;282:20143085. - PMC - PubMed
    1. Respiratory syncytial virus in children: epidemiology and clinical impact post-COVID-19. Rice E, Oakes DB, Holland C, Moore HC, Blyth CC. Curr Opin Infect Dis. 2023;36:522–528. - PubMed

LinkOut - more resources